Maiwald, one of Germany’s leading intellectual property law firms, has appointed Dr. Gisela Gerstberger as partner with effect from October 1, 2024, thereby expanding its growing Pharma & Biotech division at partner level.
Dr. Gisela Gerstberger joined Maiwald in 2016, before being promoted to counsel in 2018. Alongside the practice areas Pharma & Biotech, she specializes in organic chemistry & polymers. Gisela draws on many years of experience gained in various IP law firms and in the patent department of an international corporation. She supports clients in developing and securing their intellectual property portfolios and advises on all matters of patent law. Her main areas of expertise are patent prosecution, filing strategies (especially at international level), drafting applications, preparing freedom-to-operate and validity opinions and conducting opposition and nullity proceedings.
Gisela Gerstberger studied chemistry at the Technical University of Munich, obtaining her doctorate in the field of inorganic chemistry and organometallic catalysis. After completing her studies in “Law for Patent Lawyers” at the FernUniversität Hagen, she was admitted as a German patent attorney in 2019 and as a European patent attorney in 2020. Gisela was admitted to practice before the Unified Patent Court (UPC) in 2024.
“We are very pleased to have Gisela on board as a partner as we further strengthen our important Pharma & Biotech division. Thanks to her many years of experience and her work in the patent department of an international corporation, Gisela is very familiar with her clients’ internal processes and structures, making her excellently placed to respond to their individual needs. We wish Gisela all the best and much success in her new role,” says Dr. Eva Ehlich, partner at Maiwald.
